didn't come across this earlier, but here is the post news from Leerink with a target of $30. This was made Earlier in the month, but before earnings.:
October 8, 2010 10:04 AM EDT
Leerink Swann initiates coverage on NxStage Medical (NASDAQ: NXTM) with an Outperform rating. PT $30.
Leerink analyst says, "NXTM is essentially pioneering the home hemodialysis market with its System One, the only fully portable device on the market to treat patients with end stage renal disease (ESRD). In our view, with NXTM poised to grow sales at 15%-20% for the next few years---at a time when such lower-risk, higher-growth MedTech stories are scarce---the shares warrant a premium to other small-cap MedTech stocks."